Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries India Globalization Capital Inc (NY: IGC ) 0.3690 -0.0063 (-1.68%) Official Closing Price Updated: 8:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about India Globalization Capital Inc < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease August 22, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease August 22, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist August 20, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist August 20, 2024 From IGC Pharma Via Business Wire BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report August 09, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property IGC Pharma Reports First Quarter Fiscal 2025 Results August 08, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Buy’ Recommendation in AGP’s Analyst Coverage Research Report July 18, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target July 18, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc.’s (NYSE American: IGC) TGR-63 Demonstrates Blood-Brain Barrier Permeability in Preliminary Findings July 09, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile July 09, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Positive Data from TGR-63 Preclinical Studies June 26, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Financial Report for Fiscal Year June 25, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease June 25, 2024 From IGC Pharma, Inc. Via Business Wire IGC Reports Financial Results for Fiscal Year Ended March 31, 2024 June 24, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Execs Slated to Present at Upcoming Ascendiant Capital Markets Event June 18, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets June 18, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Publication of Key Study in European Journal June 10, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol June 10, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Initiates Patient Enrollment in Phase 2 Trial Investigating IGC-AD1 May 28, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1 May 28, 2024 From IGC Pharma Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Management Hosting Meetings at Upcoming BIO International Convention 2024 May 22, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma to Attend BIO International Convention 2024 May 21, 2024 From IGC Pharma Inc. Via Business Wire 6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings May 09, 2024 By Faith Ashmore, Benzinga Via TheNewswire.com Topics Cannabis Exposures Cannabis Product Safety BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Shares Positive Interim Results on IGC-AD1 for Agitation in Alzheimer’s April 16, 2024 Via Investor Brand Network Topics Artificial Intelligence Cannabis Exposures Artificial Intelligence Cannabis IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two April 16, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial April 09, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Adds Advisor in Artificial Intelligence April 09, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Enters into $3M SPA with Leading Asset Management Company March 27, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock March 26, 2024 From IGC Pharma Inc. Via Business Wire InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Interim Results from Phase 2 Study Evaluating Treatment to Reduce Alzheimer’s Agitation March 21, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.